CSL's full-year profit has risen 11 per cent to $US1.92 billion ($A2.82 billion), driven by disease diagnosis and global demand for its immunoglobulin portfolio.
CSL's full-year profit has risen 11 per cent to $US1.92 billion ($A2.82 billion), driven by disease diagnosis and global demand for its immunoglobulin portfolio.